Что проверяется в этом испытании
The companion study to the sickle cell trial, in people with beta thalassemia who needed regular blood transfusions to live. The question was whether editing their own stem cells would let them stop. Most participants became transfusion-independent.
An open-label, single-arm Phase 2/3 study of exagamglogene autotemcel in patients aged 12–35 with transfusion-dependent beta thalassemia. The primary endpoint was transfusion independence, defined as maintaining a weighted average haemoglobin of at least 9 g/dL without transfusion for at least 12 consecutive months.
Sources
- New England Journal of Medicine · 2024
Exagamglogene autotemcel for transfusion-dependent β-thalassemia ↗